<DOC>
	<DOCNO>NCT02797119</DOCNO>
	<brief_summary>TRACES trial multicenter randomize double blind placebo control therapeutic pharmaco-biological dose range study measure effect blood loss reduction single intravenous infusion two dos regimen ( standard dose low dose ) TA administer onset active PPH ( &gt; 800mL ) elective non-emergent CS correlate clinical effect biological effect fibrinolysis inhibition pharmacodynamic measure TA uterine bleed venous blood concentration .</brief_summary>
	<brief_title>Tranexamic Acid Reduce Blood Loss Hemorrhagic Caesarean Delivery</brief_title>
	<detailed_description>Postpartum hemorrhage ( PPH ) lead cause maternal death . Tranexamic acid ( TA ) ( ExacylÂ® Sanofi France ) , antifibrinolytic drug , reduce bleed transfusion need major surgery trauma ( 1 ) . In ongoing PPH follow vaginal delivery ( 2 ) , high dose TA decrease volume duration PPH , transfusion need maternal morbidity , early fibrinolysis inhibit ( 3 ) . Prophylactic use TA limit postoperative bleeding elective non hemorrhagic caesarean section ( CS ) . ( 1 , 4 ) TA efficiency hemorrhagic caesarean context previously publish . TA dose range vary 2,5 100 mg/kg side effect observe large dos . ( 1,4 ) Pharmacokinetics old data concern non hemorrhagic patient . ( 1 ) WOMAN ongoing international trial use one gram dose mortality reduction objective . ( 5 ) The optimal dose ongoing caesarean PPH determine . Aim study : The aim multicenter randomize double blind placebo control therapeutic pharmaco-biological dose range study TRACES measure effect blood loss reduction single intravenous infusion two dos regimens TA administer onset active PPH ( &gt; 800mL ) elective non-emergent CS correlate clinical effect biological effect fibrinolysis inhibition pharmacodynamic measure TA uterine bleed venous blood concentration . Statistical method : The sample size computation base expect difference placebo group low dose . On base EXADELI trial result , investigator calculate total 342 subject ( 114 per group ) require , For main objective , blood loss volume measure experimental group ( low dose high dose ) compare placebo group use analysis covariance adjust baseline blood loss volume . In case non-normal distribution , relative blood loss volume calculate compare use Mann-Whitney U test . Analyses do intention-to-treat basis statistical test perform 2-tailed alpha risk 0.05 . The sample size computation pharmaco-biological substudy calculate regard inhibition fibrinolysis ( D Dimers increase 30 120 minute negative null ( EXADELI trial 11 ) ) . The NNS substudy 48 patient 3 hemorrhagic group 48 patient reference non-hemorrhagic group total 192 patient . These substudy hemorrhagic patient select experimental group first 144 patient TA concentration plasmin peak specific sample complete regard blood collection congelation organisation center . Expected research benefit : The project aim answer current clinical practice question : Timing dose TA reduce blood loss maternal morbidity due active hemorrhage CS order determine optimal minimal TA dose obtain good efficacy limitation side-effects .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Pregnancy Complications</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Experimental group : Each patient experience bleeding volume 800 mL due surgery atony uterine elective nonemergent caesarean section complete information consent signature . cover social security . Reference nonhemorrhagic group : Each patient experience bleeding volume strictly less 800 mL elective nonemergent caesarean section complete information consent signature . cover social security . Patient unable consent ( &lt; 18 year old incapable people specially protect mentioned article L11215 L11218 ) RCP medical contraindication tranexamic acid Hypersensibility product excipient , Previous ongoing arterial venous thrombosis , Coagulopathy , except DIC associate predominant fibrinolytic profile , Renal failure , Previous seizures , intrathecal intraventricular administration . Obstetrical contraindication TA Severe HELLP syndrome ( platelet count &lt; 50 000/m3 renal failure prior caesarean ( RIFLE score &gt; 2 ) Protocol relate contraindication inclusion Emergent caesarean section Administration TA inclusion Inherited haemorrhagic disease low molecular weight heparin within 24 hour inclusion Previous inclusion interventional trial since 2 month CS</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Tranexamic acid</keyword>
	<keyword>Fibrinolysis</keyword>
	<keyword>Cesarean section</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>D dimer</keyword>
	<keyword>Fibrinogen</keyword>
	<keyword>Plasmin</keyword>
	<keyword>Transfusion</keyword>
</DOC>